• Product nameAnti-LITAF antibody
    See all LITAF primary antibodies
  • Description
    Rabbit polyclonal to LITAF
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Cow
  • Immunogen

    Recombinant protein fragment corresponding to a region within amino acids 1 - 132 of Human LITAF (NP_004853).

  • Positive control
    • HepG2 and HeLa cell lysates



Our Abpromise guarantee covers the use of ab96338 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 17 for isoform 1 , for isoform 2, 24 kDa.


  • FunctionProbable role in regulating transcription of specific genes. May regulate through NFKB1 the expression of the CCL2/MCP-1 chemokine. May play a role in tumor necrosis factor alpha (TNF-alpha) gene expression.
  • Tissue specificityUbiquitously and abundantly expressed. Expressed predominantly in the placenta, peripheral blood leukocytes, lymph nodes and spleen.
  • Involvement in diseaseDefects in LITAF are the cause of Charcot-Marie-Tooth disease type 1C (CMT1C) [MIM:601098]. CMT1C is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT1 group are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.
    Note=Defects in LITAF may be involved in extramammary Paget disease (EMPD) carcinogenesis. EMPD is a cancerous disease representing about 8% of all malignant skin cancers; it usually appears in the anogenital area and can be fatal by metastasizing to internal organs when left untreated for a long time. The clinical features are usually those of eczematous eruptions with weeping and crust formation.
  • DomainThe WW-binding motif mediates interaction with WWOX and, probably NEDD4.
  • Cellular localizationLysosome membrane. Associated with membranes of lysosomes.
  • Information by UniProt
  • Database links
  • Alternative names
    • Lipopolysaccharide induced TNF alpha factor antibody
    • CMT1C antibody
    • FLJ38636 antibody
    • Lipopolysaccharide induced TNF alpha factor antibody
    • Lipopolysaccharide induced TNF factor antibody
    • Lipopolysaccharide induced tumor necrosis factor alpha factor antibody
    • Lipopolysaccharide-induced tumor necrosis factor-alpha factor antibody
    • LITAF antibody
    • LITAF_HUMAN antibody
    • LPS induced TNF alpha factor antibody
    • LPS-induced TNF-alpha factor antibody
    • MGC116698 antibody
    • MGC116700 antibody
    • MGC116701 antibody
    • MGC125274 antibody
    • MGC125275 antibody
    • MGC125276 antibody
    • p53 induced gene 7 protein antibody
    • p53-induced gene 7 protein antibody
    • PIG 7 antibody
    • PIG7 antibody
    • SIMPLE antibody
    • Small integral membrane protein of lysosome/late endosome antibody
    • TP53I7 antibody
    • Tumor protein p53 inducible protein 7 antibody
    see all

Anti-LITAF antibody images

  • Anti-LITAF antibody (ab96338) at 1/1000 dilution + HepG2 whole cell lysate at 30 µg

    Predicted band size : 17 for isoform 1 , for isoform 2, 24 kDa

References for Anti-LITAF antibody (ab96338)

ab96338 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab96338.
Please use the links above to contact us or submit feedback about this product.